Riskpilot← Back to searchSign inGet full accessGalland Flebologi AB
ABActiveOrg 5567288187Sveavägen 13-15 HötorgscityGeneral medical practice activities · NACE 8621Est. 20070 employees
Revenue 2024
SEK 0
EBITDA margin
—
+2% vs 2023
Equity ratio
87.4%
Financial strength
Net profit 2024
SEK 247K
+7% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -11K | +2% |
| Net profit | SEK 247K | +7% |
| Total assets | SEK 406K | +3% |
| Equity | SEK 355K | +5% |
| Employees | 0 | — |
Legal name
Galland Flebologi AB
Org number
5567288187
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
25 april 2007
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolagets verksamhet skall vara att bedriva sjukvård, köpa, sälja och förvalta fast egendom och värdepapper samt äga och förvalta lös egendom ävensom idka därmed förenlig verksamhet.
Address
Sveavägen 13-15 Hötorgscity
Email
brigitte.perhard@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −40 | −25 | −12 | −11 | −11 |
| Depreciation & amort. | −0 | −0 | — | — | −0 |
| EBIT | −40 | −25 | −12 | −11 | −11 |
| Net financials | 156 | 311 | 334 | 303 | 318 |
| Profit before tax | 314 | 287 | 322 | 291 | 307 |
| Tax | −69 | −59 | −66 | −60 | −60 |
| Net profit | 245 | 228 | 256 | 231 | 247 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 392 | 441 | 461 | 393 | 406 |
| Equity | 354 | 331 | 357 | 338 | 355 |
| Long-term debt | 0 | 0 | — | — | 0 |
| Short-term debt | 38 | 110 | 104 | 55 | 51 |
| Total debt | 38 | 110 | 104 | 55 | 51 |
EBITDA margin
-1100000.0%
This company
15.8%
Market median
-6962125% vs market
20202024
Equity ratio
87.4%
This company
38.2%
Market median
+129% vs market
20202024
Return on equity
69.6%
This company
18.4%
Market median
+278% vs market
20202024
Net profit margin
24700000.0%
This company
8.1%
Market median
+304938172% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.14×
This company
0.62×
Market median
+77% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Galland Flebologi AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Erik Perhard | Deputy Board Member | 0 companies |
| Brigitte Galland Perhard | Board of Directors | 0 companies |